NCT05425550View on ClinicalTrials.gov

Evaluation of the Medidux™ Digital Health Application in Patients With HER2-positive Breast Cancer.

NATerminatedINTERVENTIONAL
Enrollment

196

Participants

Timeline

Start Date

August 29, 2022

Primary Completion Date

June 5, 2025

Study Completion Date

June 5, 2025

Conditions
Breast Cancer
Interventions
DEVICE

medidux™ app

Use of the regular medidux™ application for 12 (maximum 16) weeks

Trial Locations (1)

8810

Seespital Horgen-Onkologie, Horgen

Sponsors
All Listed Sponsors
collaborator

Mobile Health AG

INDUSTRY

lead

Palleos Healthcare GmbH

INDUSTRY

NCT05425550 - Evaluation of the Medidux™ Digital Health Application in Patients With HER2-positive Breast Cancer. | Biotech Hunter | Biotech Hunter